Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 52

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 52
---
 periods prior to the closing of the acquisition.
Revium Rx, which includes consolidation of Lipovation subsequent to the acquisition, is the “Successor” for periods after
the closing of the Business Combination.

As a result of the application of the acquisition method of accounting in the Successor period, the financial data for the Successor period are presented on a full step-up basis as a result of the acquisition and are therefore not comparable to the financial statements of the Predecessor period that are not presented on the same full step-up basis.

Overview

The following tables present selected financial data for the Successor period from July 24, 2024 through September 30, 2024, the Predecessor period from January 1, 2024 through July 23, 2024, as combined for the year ended December 31, 2023 and the year ended December 31, 2022.

|                                     |     | Successor             
 through September 30, 
 2024                  |                   For the 
 period commencing July 24 |   |     | Predecessor 
 through     
 July 23,    
 2024        | For the period commencing January 1 |     | For the year ended 
 December 31,       
 2023               |       |   |     | 2022    |     |   |
|:------------------------------------|:----|:----------------------|--------------------------:|:--|:----|:------------|------------------------------------:|:----|:-------------------|------:|:--|:----|:--------|----:|:--|
|                                     |     | Unaudited             |                           |   |     | Audited     |                                     |     | Audited            |       |   |     | Audited |     |   |
| Operating expenses                  |     |                       |                           |   |     |             |                                     |     |                    |       |   |     |         |     |   |
| Research and development expenses   |     |                       |                       331 |   |     |             |                               1,162 |     |                    |   846 |   |     |         | 324 |   |
| General and administrative expenses |     |                       |                       464 |   |     |             |                                 257 |     |                    |   156 |   |     |         | 112 |   |
| Operating loss                      |     |                       |                       795 |   |